Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth
96% of 23 healthcare companies beat EPS estimates, 70% posted Y/Y earnings growth. All 23 showed Y/Y revenue growth. AbbVie (ABBV), Eli Lilly (LLY), Bristol Myers (BMY), Gilead (GILD), Regeneron (REGN), Biogen (BIIB), Illumina (ILMN) reported strong Q3 results, raising outlooks. Amgen (AMGN), Pfizer (PFE), others to report next week.
How this was made
The 30-second read
Why it matters
Overall beat rates (96% EPS, 91% revenue) indicate sector strength, but individual guidance varies.
Market read
Health‑care earnings beat fuels sector optimism, likely supporting related ETFs and indices.
What to watch
Potential headwinds from pricing pressures and regulatory scrutiny could temper upside.
Background
Quarterly earnings season for health‑care sector, with most S&P 500 health stocks reporting Q3 results.
Ticker impact
Q3 revenue $17.40B beat consensus, EPS $3.82 beat $3.77, raised FY2026 EPS guidance.
upward pressure as market prices in higher guidance
Beat estimates and guidance raise suggest stronger future cash flow.
Q3 revenue $24.40B up 39% YoY, EPS $7.48 beat $5.60, raised FY2026 revenue outlook to $91‑$92B.
likely rally on robust growth and outlook
Revenue beat and higher outlook signal continued momentum.
Q3 revenue $13.07B beat, EPS $1.35 beat $1.09, raised FY2026 revenue outlook, lowered EPS forecast to $6.35‑$6.55.
mixed pressure; revenue boost offset by EPS downgrade
Conflicting signals may lead to modest net effect.
Q3 revenue $8.30B beat, non‑GAAP EPS $2.55 beat $2.17, raised FY2026 product sales outlook to $31‑$31.3B.
upward pressure from stronger guidance
Guidance lift indicates continued growth in key products.
Q3 revenue $5.12B beat, EPS $20.07 beat $16.25, strong sales of Dupixent, Eylea HD, Libtayo.
likely rally on impressive profit beat
High EPS beat signals robust demand for flagship drugs.
Q3 revenue $2.8B beat, non‑GAAP EPS $2.62 beat $1.98, raised lower end of FY2026 EPS outlook to $12.20.
upward pressure as outlook improves
Guidance raise is modest but supports upside.
Q3 revenue $1.13B beat, GAAP EPS $1.43 vs $0.98 a year ago, raised FY2026 revenue to $4.64‑$4.66B and EPS to $5.40‑$5.45.
upward pressure from improved outlook
Guidance lift signals confidence in sequencing growth.
Market effects
Broad health‑care sector shows strong earnings momentum, supporting sector ETFs.
U.S. health‑care stocks likely lead gains in major indices.
Positive U.S. health‑care results may boost global biotech sentiment.
Counterpoint
Some guidance cuts (e.g., BMY EPS) suggest caution on high‑growth expectations.
Key entities
- companyAbbVie
Pharmaceutical firm with strong Skyrizi and Rinvoq sales.
- companyEli Lilly
Drugmaker benefiting from Mounjaro and Zepbound demand.
- companyBristol Myers Squibb
Producer of Eliquis and other growth portfolio drugs.
